Up next

Autoplay

Gram-Negative NIs: Vabomere and the TANGO II Study

3 Views • 08/24/25
Share
Side Effects
Side Effects
Subscribers
0

Peter L. Salgo, MD; Jason Pogue, PharmD, BCPS-AQID; and Andrew Shorr, MD, discuss the recent approval of Vabomere, a combination of meropenem and vaborbactam, in the setting of gram-negative nosocomial infections based on the positive study results of the TANGO II trial.

Show more
0 Comments sort Sort By

Up next

Autoplay